These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18567004)

  • 1. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening.
    Goetz CG; Fan W; Leurgans S
    Mov Disord; 2008 Aug; 23(11):1541-5. PubMed ID: 18567004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The malignant course of "benign hallucinations" in Parkinson disease.
    Goetz CG; Fan W; Leurgans S; Bernard B; Stebbins GT
    Arch Neurol; 2006 May; 63(5):713-6. PubMed ID: 16682540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease psychosis 2010: a review article.
    Friedman JH
    Parkinsonism Relat Disord; 2010 Nov; 16(9):553-60. PubMed ID: 20538500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subthalamic nucleus stimulation does not cause deterioration of preexisting hallucinations in Parkinson's disease patients.
    Yoshida F; Miyagi Y; Kishimoto J; Morioka T; Murakami N; Hashiguchi K; Samura K; Sakae N; Yamasaki R; Kawaguchi M; Sasaki T
    Stereotact Funct Neurosurg; 2009; 87(1):45-9. PubMed ID: 19174620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis.
    Merims D; Balas M; Peretz C; Shabtai H; Giladi N
    Clin Neuropharmacol; 2006; 29(6):331-7. PubMed ID: 17095896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does seasonal variation affect hallucinations in PD? A longitudinal study.
    Goetz CG; Li JM; Wuu J; Leurgans S
    Mov Disord; 2006 Jun; 21(6):863-5. PubMed ID: 16538649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hallucinations and psychosis in Parkinson's disease.
    Rabey JM
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S105-10. PubMed ID: 20123547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 12-year population-based study of psychosis in Parkinson disease.
    Forsaa EB; Larsen JP; Wentzel-Larsen T; Goetz CG; Stebbins GT; Aarsland D; Alves G
    Arch Neurol; 2010 Aug; 67(8):996-1001. PubMed ID: 20697051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.
    Onofrj M; Thomas A; Bonanni L
    Expert Rev Neurother; 2007 Dec; 7(12):1731-50. PubMed ID: 18052766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hallucinations and psychosis in Parkinson's disease.
    Eng ML; Welty TE
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):316-30. PubMed ID: 20869621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors and course of health-related quality of life in Parkinson's disease.
    Forsaa EB; Larsen JP; Wentzel-Larsen T; Herlofson K; Alves G
    Mov Disord; 2008 Jul; 23(10):1420-7. PubMed ID: 18512757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hallucinations in Parkinson's disease: a follow-up study.
    de Maindreville AD; Fénelon G; Mahieux F
    Mov Disord; 2005 Feb; 20(2):212-7. PubMed ID: 15390044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.
    Fabbrini G; Barbanti P; Aurilia C; Pauletti C; Lenzi GL; Meco G
    Neurol Sci; 2002 Apr; 23(1):41-3. PubMed ID: 12111620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.
    Tagai K; Nagata T; Shinagawa S; Tsuno N; Ozone M; Nakayama K
    Psychogeriatrics; 2013 Jun; 13(2):103-7. PubMed ID: 23909968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease.
    Biglan KM; Holloway RG; McDermott MP; Richard IH;
    Neurology; 2007 Jul; 69(2):187-95. PubMed ID: 17620552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rivastigmine as adjunctive therapy in the therapeutic dilemma for the treatment of hallucinations due to Parkinson disease].
    Rovers JM; Dautzenberg PL; ter Bruggen JP
    Tijdschr Gerontol Geriatr; 2006 Jul; 37(3):117-20. PubMed ID: 16886519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When a Parkinson's disease patient starts to hallucinate.
    Poewe W
    Pract Neurol; 2008 Aug; 8(4):238-41. PubMed ID: 18644910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.